journal article·2017-08-18Open access

Toxicity, pharmacokinetics, andin vivoefficacy of biotinylated chitosan surface-modified PLGA nanoparticles for tumor therapy

Hongli Chen, WenBin Nan, Xiangjuan Wei, Yan Wang, Feng Lv, Hongbo Tang, Yonghai Li, Chenyan Zhou, Juntang Lin, Wuling Zhu, Qiqing Zhang

Abstract

Based on our previous work on the PLGA nanoparticles modified with biotinylated chitosan (Bio-CS-PLGA NPs), we further studied the stability, toxicity, pharmacokinetics, and in vivo efficacy. The safety of NPs was studied through single-dose toxicity test in mice, and the result showed that NPs were well tolerated at the dose of 300 mg/kg. Compared with the free EPB group, the NPs group exhibited higher plasma drug concentration, longer half-life time. EPB-loaded NPs significantly inhibited the tumor growth compared to free EPB. All results suggested that Bio-CS-PLGA NPs were stable, safe, and showed a promising potential on targeted drug delivery.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Research Center of Stem Cell and Biotherapy Technology, School of Life Science and Technology, Xinxiang Medical University, Xinxiang, China;

Institute of Biomedical Engineering, Chinese Academy of Medical Sciences, Tianjin, China;

Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China

Funding

The National Natural Sciences Foundation · The Key Technologies R&D Program of Henan Province

References (29)

Show source-provided references
1. 10.1016/j.toxlet.2016.01.01810.1016/j.toxlet.2016.01.018 ↗
2. 10.1016/B978-0-12-407173-5.00002-910.1016/B978-0-12-407173-5.00002-9 ↗
3. 10.2174/1573413711309666011310.2174/15734137113096660113 ↗
4. 10.1016/j.colsurfb.2015.11.03310.1016/j.colsurfb.2015.11.033 ↗
5. 10.1016/j.colsurfb.2009.05.02010.1016/j.colsurfb.2009.05.020 ↗
6. 10.1021/nn900002m10.1021/nn900002m ↗
7. 10.3109/21691401.2014.95510810.3109/21691401.2014.955108 ↗
8. 10.1016/j.echo.2013.10.00810.1016/j.echo.2013.10.008 ↗
9. 10.2165/00003088-200342050-0000210.2165/00003088-200342050-00002 ↗
10. 10.1016/j.carbpol.2015.12.03110.1016/j.carbpol.2015.12.031 ↗
11. 10.1002/jps.2387510.1002/jps.23875 ↗
12. 10.1016/j.biomaterials.2014.05.04010.1016/j.biomaterials.2014.05.040 ↗
13. 10.1016/j.nano.2014.08.00410.1016/j.nano.2014.08.004 ↗
14. 10.1016/j.colsurfb.2012.10.06310.1016/j.colsurfb.2012.10.063 ↗
15. 10.1016/j.phrs.2016.03.00610.1016/j.phrs.2016.03.006 ↗
16. Moghimi SM · Pharmacol Rev · 2001 · 53 · 28310.1016/S0031-6997(24)01494-7 ↗
17. 10.1002/jps.2466610.1002/jps.24666 ↗
18. 10.1126/science.111439710.1126/science.1114397 ↗
19. 10.1016/j.ijpharm.2013.06.03710.1016/j.ijpharm.2013.06.037 ↗
20. 10.1016/j.toxlet.2008.01.02010.1016/j.toxlet.2008.01.020 ↗
21. 10.1016/j.jconrel.2009.10.03210.1016/j.jconrel.2009.10.032 ↗
22. 10.3109/21691401.2014.93445610.3109/21691401.2014.934456 ↗
23. 10.3109/10717544.2010.49025010.3109/10717544.2010.490250 ↗
24. 10.1016/j.addr.2013.08.01210.1016/j.addr.2013.08.012 ↗
25. 10.1016/j.addr.2007.11.00710.1016/j.addr.2007.11.007 ↗
26. 10.1016/j.carbpol.2016.04.04110.1016/j.carbpol.2016.04.041 ↗
27. 10.1016/j.ejps.2012.04.01110.1016/j.ejps.2012.04.011 ↗
28. 10.1016/j.jconrel.2014.12.02210.1016/j.jconrel.2014.12.022 ↗
29. 10.1016/j.biomaterials.2013.11.08610.1016/j.biomaterials.2013.11.086 ↗